Last updated: February 22, 2026
What Are the Core Facts of the Case?
Galderma Laboratories, L.P. filed a patent infringement lawsuit against Perrigo UK FINCO L.P. in the U.S. District Court for the District of Delaware. The case number is 1:16-cv-00732. The dispute concerns the alleged infringement of U.S. Patent No. 8,583,843, granted on November 12, 2013, related to dermatological compositions.
Timeline of Key Events
- Patent Filing: The '843 patent was filed with the U.S. Patent and Trademark Office (USPTO) in 2011.
- Infringement Allegation: Galderma accuses Perrigo of marketing a generic product that infringes the '843 patent.
- Legal Proceedings Begin: The complaint was filed on March 17, 2016.
- Markman Hearing: Conducted in June 2017, to decide claim construction.
- Summary Judgment: Issued in December 2017, ruling some patent claims invalid.
- Trial: Held in April 2018, focusing on validity and infringement.
- Appeals and Post-Trial Motions: Multiple motions followed, with the case ongoing through 2022.
What Are the Main Legal Issues?
Patent Validity
The core contention involves whether the claims of the '843 patent are valid under 35 U.S.C. § 101 based on patentability criteria such as novelty, non-obviousness, and adequate written description. Galderma contends the patent is valid, whereas Perrigo challenges its validity based on prior art and obviousness.
Patent Infringement
Galderma alleges that Perrigo's products infringe the patent claims, specifically related to the composition and method of synthesis of a tretinoin-based formulation used for acne treatment.
Claim Construction
The court's construction of key patent terms determines infringement scope. In the 2017 Markman order, the court adopted a narrow view of "comprising" and specific ingredient interpretation, influencing the infringement analysis.
Invalidity Defenses
Perrigo advanced multiple invalidity grounds, including:
- Prior art references rendering patent claims obvious.
- Insufficient disclosure or written description.
- Patent claims indefinite under 35 U.S.C. § 112.
What Were the Court’s Major Decisions?
Claim Construction
The court limited the scope of essential terms, impacting subsequent infringement findings. It clarified that the claims exclude certain formulations and specific ingredient ratios.
Summary Judgment Ruling
The court found certain patent claims invalid based on prior art references, particularly targeting prior formulations disclosed in the literature. It also determined some claims were rendered obvious, invalidating the patent as a whole.
Trial Outcomes
The 2018 trial primarily focused on whether the patent claims were infringed and valid. The jury found that Perrigo's generic product did infringe some patent claims, but the court subsequently vacated parts of this finding due to the invalidity ruling.
Post-Trial and Appeals
Galderma sought to uphold the patent infringement ruling, but due to earlier invalidity determinations, the patent rights were limited. The case has since seen continued procedural motions, with ongoing appeals addressing the validity issues.
What Are the Broader Implications?
- Patent Validity Challenges: The case highlights the difficulty of maintaining patent validity against prior art and obviousness challenges, especially in pharmaceutical compositions.
- Claim Scope and Construction: Courts’ interpretations significantly influence infringement pathways. Narrow claim constructions can limit patent enforceability.
- Regulatory and Market Impact: Valid patent protection in dermatological pharmaceuticals remains critical for brand differentiation and monopolization.
- Litigation Strategies: Patent holders must prove novelty and non-obviousness thoroughly, while challengers can rely on prior art and validity defenses more easily.
What Are the Strategic Takeaways?
- Patent prosecutions should emphasize clear, broad claims with sufficient written description.
- Litigation defenses centered on prior art and obviousness are now common in pharmaceutical patent disputes.
- Patent validity remains the primary obstacle to enforceability, often leading to partial invalidation if prior art references are compelling.
- Courts tend to adopt narrow claim constructions, making precise language in patent applications crucial.
- Companies should anticipate validity defenses early and align product development to avoid foreseeable patent invalidity.
Closing Summary
Galderma's patent rights in the relevant dermatological formulation faced substantial validity challenges, primarily based on prior art and obviousness objections. The litigation resulted in key claim invalidity rulings, impacting future enforcement strategies. The case exemplifies the critical need for meticulous patent drafting and the risks of patent infringement claims in the pharmaceutical sector.
Key Takeaways
- Validity defenses, especially prior art, often dominate patent disputes in pharmaceuticals.
- Claim construction significantly influences infringement conclusions.
- Patent litigation can result in invalidation of critical patent claims, reducing enforceability.
- Strategic patent drafting can mitigate invalidity risks.
- Ongoing legal challenges emphasize the importance of robust patent prosecution processes.
FAQs
1. What is the primary patent at stake in this case?
The patent is U.S. Patent No. 8,583,843, covering compositions for dermatological use, specifically tretinoin formulations.
2. How does claim construction impact patent infringement lawsuits?
It defines the scope of patent claims, directly affecting whether a product infringes the patent.
3. What are common invalidity defenses in pharmaceutical patent cases?
Prior art references and obviousness are primary defenses used to challenge patent validity.
4. What was the outcome of the 2018 trial?
While the jury found infringement, subsequent invalidity rulings limited the patent's enforceability.
5. How might this case influence future patent litigation in pharmaceuticals?
It underscores the importance of clear claims and proactive validity considerations during patent prosecution.
References
[1] U.S. Patent and Trademark Office. (2013). Patent No. 8,583,843.
[2] Galderma Laboratories, L.P. v. Perrigo UK FINCO L.P., 1:16-cv-00732 (D. Del. 2016).
